Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin
Author:
Affiliation:
1. University of North Carolina at Chapel Hill, Chapel Hill, NC
2. Stanford University School of Medicine, Stanford, CA
Funder
National Cancer Institute
V Foundation for Cancer Research
Publisher
Massachusetts Medical Society
Subject
General Medicine
Link
http://www.nejm.org/doi/pdf/10.1056/NEJMc2306105
Reference5 articles.
1. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
2. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
3. A multiprotein supercomplex controlling oncogenic signalling in lymphoma
4. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
5. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma;Cancer Discovery;2024-09-03
2. Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes;Clinical Lymphoma Myeloma and Leukemia;2024-09
3. Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm;Human Pathology;2024-09
4. Genomics in Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09
5. Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to polatuzumab vedotin based therapy in patients with relapsed/refractory disease;Clinical Lymphoma Myeloma and Leukemia;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3